Avid Bioservices Inc (CDMO)

[biopharm]

I don't understand how one would like the new CDMO manufacturing methods that attracted Halozyme, yet one fails to understand how imaging is at the forefront right now, and the FDA not yet ahead of the curve to use 3D live imaging to test MOA of drugs they approve.

Sounds like a little paradigm shift in Big Pharma looming around the corner and since many here have followed PS Targeting, many would welcome imaging to put to the test the MOA of a drug like PS Targeting. If one fails to see that link...maybe there is some conflicts of interest to see PS Targeting succeed.

Dana Farber and Gordon Freeman, Clive Wood ...never said that ship had sailed and we shall see what happens next.

Remember, collaborations and biomarkers learned via PS Targeting is linked to John Springs Stafford trying to steal the IP, even if he is just the get away driver for others behind Oncologie.

_________

Dana-Farber Scores Major Legal Victory On Cancer Drug Patents Likely Worth Billions

Tasuku Honjo, left, and Gordon Freeman (courtesy Bengt Nyman/Flickr and Dana-Farber Cancer Institute)
The Dana-Farber Cancer Institute on Friday scored a major victory in Boston federal court: a ruling that one of its researchers should be listed as an inventor on six patents believed to be worth billions of dollars.

The patents are connected to immunotherapy drugs, a powerful new type of cancer treatment that unleashes a patient's own immune system against cancer.

The legal crux of the case was a dispute over a collaboration between American researchers and Japanese researchers led by Nobel Laureate Tasuku Honjo of Kyoto University. Honjo was listed as inventor on the patents, but Dana-Farber argued that the Americans — Drs. Gordon Freeman and Clive Wood — deserved to be listed on the patents as well.

One lawyer compared the case to deciding who gets credit for completing a jigsaw puzzle that includes many pieces put in by multiple players.

Given the financial stakes and the importance of the case, the verdict is likely to be appealed, says professor Jake Sherkow of New York Law School, an expert on patent disputes in the life sciences.

But at this point, "It's a total victory for Dana-Farber," he said on Friday.

"The judge's factual findings were particularly specific, and the conclusions of law were very thorough and well reasoned," he said. "So I think, given that, the likelihood of success on appeal is probably going to be scant," and the verdict is likely to stand.

One possible moral of the story, Sherkow said, is that "researchers who are engaged in long and detailed scientific collaborations with one another should be upfront about when, whether and to what extent they're applying for patents on what they view as their own contribution. Because in fact, that contribution may be a joint one."

The high-stakes legal drama pitted Honjo, 77, against another immunotherapy pioneer: Dana-Farber's Freeman, who's also a Harvard Medical School professor.

The trial focused on work done nearly 20 years ago, when some of the seminal science that led to immunotherapy was developed. The patents concerned what's called the "PD-1 pathway," which has become the basis for multiple immunotherapy drugs.

Dana-Farber, the plaintiff in the case, argued that the Americans made significant contributions and should be included on those patents. Honjo's side included the pharma giant Bristol-Myers Squibb, which now holds the licenses that control the use of those patents.

Honjo himself took the stand for hours and argued that no, he got no significant help from his American colleagues. Testimony at the trial focused heavily on the exchange of biological materials and unpublished data between the American and the Japanese researchers in 1999 and 2000.

The ruling by Judge Patti Saris reads, in part:

I find Dana-Farber has presented clear and convincing evidence that Dr. Freeman and Dr. Wood are joint inventors of the six Honjo patents. Dr. Honjo collaborated extensively with both Dr. Freeman and Dr. Wood from at least October 1999 until at least September 2000 through numerous meetings, joint authorship of scientific journal articles, written collaboration agreements, and sharing of experimental results and ideas. Indeed, Dr. Honjo himself referred to his work with Dr. Freeman and Dr. Wood as a collaboration on at least six occasions. While the relationship among these three brilliant scientists eventually soured, all three made significant contributions to the inventions.
Dana-Farber says in a press release:

The decision will enable Dana-Farber to license the technology, which is currently embodied in several of the newest immunotherapy drugs, to additional companies seeking to develop PD-1 and PD-L1 antibody therapeutics for a wide range of cancers.

https://www.google.com/amp/s/amp.wbur.org/commonhealth/2019/05/17/dana-farber-cancer-immunotherapycourt-victory
______


COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ENTRY
Publication number: 20150297677
Abstract: The invention provides methods, compositions, and kits featuring agents that inhibit viral entry mediated by T-cell Immunoglobulin and Mucin-domain containing proteins (TIM proteins) and other phosphatidylserine receptors.

Type: Application
Filed: December 12, 2013
Publication date: October 22, 2015

Applicant: Children Medical Center Corporation

Inventors: Hyeryun Choe, Stephanie Jemielity, Dale T. Umetsu, Rosemarie H. De Kruyff, Gordon J. Freeman

______